A Prospective, Multicenter, Single-arm, Open-label, Phase 4 Study to Evaluate the Effects of Macitentan on Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension Assessed by Cardiac Magnetic Resonance Imaging
Phase of Trial: Phase IV
Latest Information Update: 26 May 2017
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Acronyms REPAIR
- Sponsors Actelion Pharmaceuticals
- 19 May 2017 Planned End Date changed from 1 Jun 2018 to 31 May 2019.
- 19 May 2017 Planned primary completion date changed from 1 Dec 2017 to 31 Oct 2018.
- 06 Jul 2016 Planned End Date changed from 1 Apr 2017 to 1 Jun 2018.